At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
Eltrombopag Olamine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Eltrombopag in Patients Undergoing Cord Blood or Haploidentical Bone Marrow Transplantation
In Brief
A Phase 2 clinical trial evaluating Eltrombopag Olamine and Laboratory Biomarker Analysis for Bone Marrow Transplantation Recipient and 2 related conditions. Completed, enrolled 48 participants across 1 site.
Detailed Summary
This phase II trial studies how well eltrombopag olamine works in increasing platelet counts in patients undergoing transplant. Eltrombopag olamine may help platelet counts and the immune system recover from blood or bone marrow transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBone Marrow Transplantation Recipient, Cord Blood Transplant Recipient, Hematopoietic Cell Transplantation Recipient
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 2013
Enrollment StartOct 2013
Primary CompletionJun 2023
TodayJul 2026
First PostedAug 23, 2013
Enrollment StartOct 14, 2013
Primary CompletionJun 6, 2023
TodayJul 2, 2026
Enrollment to primary: 9.6 yearsPosted 12.9 years ago
Interventions
Eltrombopag Olaminedrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies